NAGLAZYME 5 mg/5mL
galsulfase · SOLUTION · BioMarin Pharmaceutical Inc.
Naglazyme (galsulfase) is an intravenous enzyme replacement therapy used to treat mucopolysaccharidosis VI (MPS VI), a rare genetic disorder in which the body cannot break down certain complex sugars. This medication helps reduce the buildup of these substances in the body to improve symptoms and slow disease progression.
Key Facts
- Brand Name
- NAGLAZYME
- Generic Name
- galsulfase
- NDC Code (Product)
68135-020- Manufacturer
- BioMarin Pharmaceutical Inc.
- Strength
- 5 mg/5mL
- Dosage Form
- SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125117
- Drug Class
- Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC]
- Marketing Start
- 06/09/2005
Recall History
No Recall HistoryFrequently Asked Questions
What is NAGLAZYME used for?
Naglazyme (galsulfase) is an intravenous enzyme replacement therapy used to treat mucopolysaccharidosis VI (MPS VI), a rare genetic disorder in which the body cannot break down certain complex sugars. This medication helps reduce the buildup of these substances in the body to improve symptoms and slow disease progression.
Is NAGLAZYME a controlled substance?
NAGLAZYME is not classified as a controlled substance by the DEA.
What is the generic name for NAGLAZYME?
The generic name for NAGLAZYME is galsulfase. There are no other listed brand versions of galsulfase.
What is the NDC code for NAGLAZYME 5 mg/5mL?
The NDC (National Drug Code) for NAGLAZYME 5 mg/5mL is 68135-020, listed by BioMarin Pharmaceutical Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)